PharMerica (PMC) Receiving Somewhat Favorable Press Coverage, Analysis Shows

News headlines about PharMerica (NYSE:PMC) have been trending somewhat positive on Tuesday, according to Accern. The research firm scores the sentiment of news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. PharMerica earned a media sentiment score of 0.17 on Accern’s scale. Accern also gave news headlines about the company an impact score of 46.2306948774717 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Shares of PharMerica (NYSE:PMC) opened at $29.25 on Tuesday. The firm has a market cap of $910.27, a P/E ratio of 47.95, a P/E/G ratio of 1.27 and a beta of 0.82. The company has a debt-to-equity ratio of 0.79, a current ratio of 2.58 and a quick ratio of 1.79. PharMerica has a one year low of $22.00 and a one year high of $29.50.

PharMerica (NYSE:PMC) last announced its earnings results on Thursday, November 9th. The company reported $0.46 earnings per share for the quarter, missing analysts’ consensus estimates of $0.49 by ($0.03). The company had revenue of $595.10 million during the quarter, compared to analysts’ expectations of $596.80 million. PharMerica had a net margin of 0.54% and a return on equity of 2.30%. equities analysts anticipate that PharMerica will post 1.92 EPS for the current fiscal year.

PMC has been the topic of a number of recent analyst reports. Zacks Investment Research downgraded shares of PharMerica from a “buy” rating to a “hold” rating in a research note on Tuesday, September 26th. ValuEngine downgraded shares of PharMerica from a “buy” rating to a “hold” rating in a research note on Friday, September 22nd. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the company’s stock. PharMerica presently has an average rating of “Hold” and a consensus price target of $30.50.

In other PharMerica news, CEO Gregory S. Weishar sold 521,089 shares of PharMerica stock in a transaction that occurred on Thursday, December 7th. The shares were sold at an average price of $29.25, for a total transaction of $15,241,853.25. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders have sold 532,089 shares of company stock worth $15,242,873 over the last three months. Insiders own 5.04% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was reported by Community Financial News and is the property of of Community Financial News. If you are viewing this article on another publication, it was stolen and republished in violation of US and international copyright legislation. The legal version of this article can be viewed at https://www.com-unik.info/2018/01/02/pharmerica-pmc-receiving-somewhat-favorable-press-coverage-analysis-shows.html.

About PharMerica

Insider Buying and Selling by Quarter for PharMerica (NYSE:PMC)

Receive News & Ratings for PharMerica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PharMerica and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit